Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy is a multi-ingredient nutritional and pharmaceutical regimen investigated as an adjunctive treatment for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). Developed by Mid-Atlantic Retina Consultations, Inc., the cocktail combines the tetracycline antibiotic minocycline with a specific array of dietary supplements, including inosine, various forms of vitamin E (tocopherols and tocotrienols), coenzyme Q10, niacinamide, vitamin C, N-acetyl cysteine, and a complete multivitamin. The rationale behind this combination is to leverage the anti-inflammatory and neuroprotective properties of minocycline alongside the antioxidant and metabolic support provided by the supplements to improve clinical outcomes in retinal vascular diseases. Several components are administered in sustained-release formulations to maintain consistent therapeutic levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inosine + tocopherol + tocotrienol + coenzyme Q10 + niacinamide + vitamin C + N-acetyl cysteine + multivitamin + minocycline.